Strategic Market Analysis of Indian Biosimilar Market
This Analyst Briefing will provide a brief overview of the Indian biosimilar market, highlighting the key trends, drivers, and restraints. It further highlights the emerging trends and market opportunities to enable decisions related to future strategies and investments in this segment.
This comprehensive, objective information allows your company to:
- Minimize risk
- Identify new opportunities
- Drive effective strategies for growth
RecordedDec 14 201136 mins
Your place is confirmed, we'll send you email reminders
Frost & Sullivan predicts the $100 genome will be achieved by 2024 should new technology launches continue at the current pace. This milestone will disrupt the services space both positively and negatively, as some customers will opt to bring sequencing in-house at that price point, while others that continue to outsource will greatly expand their large-scale sequencing projects. A new business model of answer-based sequencing services is likely to emerge in 10 years.
Divyaa Ravishankar, Paul Pickering, CEO, Ubiquitome, Herbert Torfs, VP Business Development and Strategy, GenePOC
This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the point-of-care testing industry. We will also be joined by Paul Pickering, president and CEO, Ubiquitome, and Herbert Torfs, VP Business Development and Strategy, GenePOC, who will discuss their experience with market trends, regulatory road blocks, and unaddressed needs in the US, Europe, and developing and underdeveloped nations.
Frost & Sullivan Transformational Health Team, Chris Chen, CEO, WuXi Biologics, Steve Lam, Senior Vice President, Patheon
Questions this briefing will address:
· What are the key challenges the CMOs are likely to face in the near- and long-term future? How can CMOs strategize to overcome these hurdles?
· What growth opportunities exist in the pharmaceutical contract manufacturing industry?
· In what ways is the pharmaceutical contract manufacturing industry likely to change to meet industry trends and dynamics?
· Who are the game-changing companies, and what are the disruptive technologies and business models?
· How should CMOs strategically position their assets with pharma companies?
Transformational Health Team: Nitin Naik, Divyaa Ravishankar, Christi Bird, and Unmesh Lal
The global pharmaceutical industry is witnessing an unprecedented era. Several new demand spaces such as innovative therapeutics (immuno-oncology), clinical diagnostics (liquid biopsy), and research tools (next-generation sequencing) have emerged, driving companies to sharpen their long-term positions. Fundamental behavioral shifts in these spaces are redefining the market. Companies are adopting a “beyond-the-pill” approach and increasing investments in innovations related to drug discovery, clinical trials, supply-chain solutions, and patient engagement. This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the life sciences industry.
Why You Must Attend:
• For hospitals to succeed, it is imperative to create a strategy that allows optimal alignment of care provision between providers. There is no “one-size-fits-all approach” to remain competitive.
•This briefing assesses different strategies adopted by hospitals, which range from smart collaborations with different ambulatory care providers to efficiently manage care transition, adoption of data integration solutions to better create standards of care protocols, and launch of in-house insurance plans to increase patient volumes.
• An understanding of these strategies is critical for hospitals to create bespoke integrated care delivery solutions that can be used to address local requirements.
• This briefing also highlights the financial impact of adopting such integrated models of care delivery.
Demand for telehealth is on the rise in APAC as healthcare industry stakeholders across the region seek to address challenges of an ageing population and rising healthcare costs. However, market sustainability heavily depends on the establishment of successful business models that provide holistic health and wellness solutions by creating an ecosystem of products and services. In this briefing we will discuss the APAC Telehealth market opportunity with in-depth analysis of technologies, regulations, industry partnerships and business models that will help shape the future of care delivery in the region.
Rhenu Bhuller, Venkat Rajan,Kamaljit Behera - Frost & Sullivan
Industry convergence and technological innovations are giving rise to a new breed of wearable technologies that are capable of meeting the unique needs and requirements of clinical care settings. Unlike more prevalent general health and fitness devices, these wearables can function with higher levels of accuracy and reliability allowing them to be used by medical professionals to make assessments and recommendations for patients.
In this interactive briefing, Frost & Sullivan’s Transformational Health team will explore the future applications and opportunities for these innovations, and key strategy considerations for developers.
Dorman Followwill, Richard Weissenberg, Venkat Rajan
The healthcare industry is fundamentally influenced by the deployment of technology. More than any other industry, healthcare can benefit from the adoption, and Africa is uniquely positioned to gain from the advances. The audience will receive the following advantages by attending the presentation:
• Frost & Sullivan will share top predictions for the healthcare industry in Africa for 2016
• Learn about key trends in the African healthcare industry
• Uncover areas of opportunity in healthcare
• Participate in an interactive Q&A session
Transformational Health Team: Daniel Ruppar, Nancy Fabozzi, Victor Camlek, and Koustav Chatterjee
Connected healthcare continues to expand as innovations in technology and services flourish. Consequently, the adoption of digital health solutions has increased significantly throughout the industry.
While the U.S. healthcare system evolves and embraces lower costs and improving quality of care and access, opportunities are emerging in connected healthcare. The industry is driven by health IT development, growth of connected and savvy users, as well as cloud based- software as a service (SaaS) delivery models.
Join Frost & Sullivan’s Connected Health team, as they host a panel discussion on the 2016 connected healthcare predictions and current insights on key areas within the market. The panel will be followed by a live Q&A session. This is the first of the Connected Health team’s new quarterly webinar series.
Attend this webinar to discover:
• Key market predictions including merger and acquisitions (M&A), partnerships, as well as areas of growth and controversy in 2016
• New data regarding consumers; how they view their health and interests in digital health tools
• Latest perspectives on telehealth and remote patient monitoring
• The progression of the ambulatory electronic health records space and what this means for providers
Rhenu Bhuller - Partner & SVP, Natasha Gulati - Industry Manager, Siddharth Shah - Industry Analyst
Demand for healthcare services will continue to grow in Asia-Pacific (APAC) under the influence of demographic and epidemiological transitions impacting the entire region. APAC governments, which shoulder the largest burden of paying for healthcare services will take decisive steps towards innovating their healthcare systems so that they can be prepared for challenges of the future. This will call for a complete transformation of the way healthcare is delivered in APAC with all key stakeholders – pharma companies, device manufacturers and healthcare services providers – racing to reinvent their business models. In this briefing we present major healthcare industry trends for APAC and their impact on businesses in 2016.
Alice Borrelli, Intel; Robert Havasy, Personal Connected Health Alliance, Niklas Sundler, Telia
Across Europe, there is a high level of focus on adoption of digital health as a means to drive healthcare efficiency. In Sweden, there are several projects that have been initiated to address this challenge and there is an ongoing discussion about the role of Continua. One of the challenges in achieving the full potential of digital health is turning the data collected from a variety of sources into accessible timely information that individuals (patients, careers, clinicians and managers) can act on. Interoperability standards have an important part to play in generating this value from the investment made in data collection and storage. By using an international standard, your project won't get locked into one vendor and it will be easy to share information between systems.
Frost & Sullivan’s experts are predicting another year of big disruptions, transformations and innovations as the healthcare industry continues to overhaul outmoded business models. This annual forecast aims to help stakeholders understand key issues affecting the healthcare industry. In 2016, advances in areas ranging from wearables to blood testing as well as artificial intelligence, expect to help shape the industry.
The webinar will identify market risks and opportunities for stakeholders developing solutions connected to the pharmaceuticals, biotechnology, medical technologies, diagnostics and healthcare IT sectors that can impact industry participants.
Attend this webinar to:
- Gain insightful predictions and probative analysis of the global healthcare industry in 2016
- Discover key strategies and initiatives executed by companies to capture opportunities for solutions in health, wellness and prevention
- Track the progress of key macro level industry trends and their projected milestones for 2016
- Participate in an interactive Q&A session with Frost & Sullivan’s senior industry thought leaders
Greg Caressi, Frost & Sullivan; Chris Gough, Intel; Dr. David Delaney, SAP; Dr. Kevin Fitzpatrick, CancerLinQ
This session will share insights into how SAP’s HANA in-memory database along with Intel tailored hardware are being leveraged by the American Society of Clinical Oncology, to bring genome aware medicine to cancer patients everywhere.
Policies in ASEAN are directed towards creating a single ASEAN market. It will be achieved through individual national initiatives to increase the competitiveness of their nation, providing a single window to access an estimated 671.6 million consumers with a combined estimated GDP per capita of $6,552 in 2020.
The study of the TOP 6 policies in ASEAN reveals their impact towards healthcare delivery value chain from manufacturer and suppliers to the hospitals and insurers, and where opportunities for growth, diversification and change of business models are expected.
Expected tangible insights:-
•ASEAN Healthcare Market – Size and Projected Growth
•Stages of development and compliances to policies
•Insights and analysis of the following:-
oASEAN Economic Community
oASEAN Medical Device Directive
oUniversal Health Coverage in Indonesia
oOnline-Catalogue and Purchasing
oThailand Medical Hub
oMyanmar Companies Act
•Market Opportunities and Risks
•Game Changing Environments
Shawn Dolley, Cloudera; Chris Gough, Intel and Vijay Venkatesan, Sutter Health
- Hear examples of unstructured data types most commonly added to healthcare Big Data implementations
- From the semantic web to ICU audio files, which are the most interesting data sources inside and outside of the clinic
- The coolest ‘v’ of the four ‘v’s of Big Data is variety; hear best practices on adding this to a data lake
- Predicting readmission and sepsis has proliferated, what’s next?
- Data science is now mainstream and much easier in a Big Data sandbox, what’s the easiest way to set this up in healthcare?
Sowmya Srinath, Research Manager and Tanvir Jaikishen, Senior Research Analyst
It is a known fact that Europe’s Big 5 Health Systems are in transition. The transition is plagued by resource shortages, funding deficiencies, and demand increase from the patient population. The transition can never be a one-size-fits-all solution. Efficiency is not the solution to all of the issues.
This webinar will assess the evolution of these health systems to understand if changes in care provision reflect sound policy making or are a knee-jerk response to changing external factors.
Tod Davis, Children’s Healthcare of Atlanta; Amandeep Khurana, Cloudera and Chris Gough, Intel Health & Life Sciences
Hear perspectives and insights from industry thought leaders regarding:
- Hype vs. reality in real world applications of ‘big data’ systems in healthcare delivery?
- Why now?
- Through case studies some examples of plausible expectations for the scale and timeframe of ROI.
- What changes in operations , infrastructure, and protocol is required to ensure maximum value of invested technologies?
Jane Andrews, Ph.D., senior consultant, Healthcare & Life Science
Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market; it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.
Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world’s aging populations. In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.
Jane Andrews, Ph.D ; Sanjeev Kumar ; Rhenu Bhuller
Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.
Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.
The Asia Pacific is the third largest pharmaceutical market in the world after North America and Europe, with generics being the major driver for the pharmaceutical industry in this region, aided by factors such as the aging population and impending expiry of patented drugs. It is a necessity for pharmaceutical companies to be aware of the key trends in the APAC generics market and maximise the market opportunities in order to remain relevant.
In today’s rapidly evolving business landscape, pharmaceutical companies are also starting to realise the importance of the customer experience as a key differentiator. With a gradual shift from product to the customer, the pharmaceutical industry needs to keep up with other industries in terms of providing the perfect digital customer experience. A well-executed digital strategy is essential for today’s pharmaceutical companies to better connect with their clients.
Our Helthcare webcasts cover Connected Health, Life Sciences and Advanced Medical Technologies to help you to better understand buyer-seller dynamics as the healthcare system transitions to digital information, the pace at which new and innovative medical devices and systems are being adopted and getting embedded into the typical clinical pathway, both in mature and emerging markets, and enables you to bring clarity to pharmaceutical/biotechnology, in-vitro diagnostics and life science research tools market decisions and implementation tactics.